U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498959) titled 'Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer' on March 17.
Brief Summary: The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is:
Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
Study Start Date: March 19
Study...